CG Oncology CEO highlights biotech’s oncolytic immunotherapy for bladder cancer

Urinary system, bladder, kidney

CG Oncology CEO Arthur Kuan talked about the biotech company’s experimental bladder cancer treatment in Phase 3 development and collaboration with Merck, among the company’s milestones, in response to emailed questions.